Abbott Laboratories vs Amgen at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABT | AMGN |
|---|---|---|
| Market cap | $196.04B | $235.24B |
| Price | $112.47 | $432.42 |
| P/E ratio (TTM) | 33.47 | 22.89 |
| P/B ratio (MRQ) | 4.19 | 20.38 |
| P/S ratio (TTM) | 4.93 | 4.8 |
| Revenue growth (1Y) | 5.67% | 9.92% |
| Return on equity (TTM) | 12.51% | 89.06% |
| Return on invested capital (TTM) | 9.36% | 14.50% |
| Gross margin (TTM) | 56.80% | 72.65% |
| Net margin (TTM) | 11.65% | 22.93% |
| Dividend yield (TTM) | 2.24% | 2.33% |
How they differ
Amgen is the larger company at $235.24B versus $196.04B, making them close in size.
On trailing earnings, Amgen is the cheaper of the two at 22.89 against 33.47 for Abbott Laboratories.
On sales, Amgen is the cheaper of the two at 4.8 against 4.93 for Abbott Laboratories.
Amgen leads on revenue growth over the past year, 9.92% against 5.67%.
Amgen leads on return on invested capital, 14.50% against 9.36%.
Amgen leads on gross margin, 72.65% against 56.80%.
Amgen offers the higher yield at 2.33% against 2.24%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Abbott Laboratories or Amgen.